Beyond oncology: Selinexor's journey into anti-inflammatory treatment and long-term management
D Li, H Fang, R Zhang, Q Xie, Y Yang… - Frontiers in …, 2024 - frontiersin.org
Selinexor, a selective inhibitor of nuclear export (SINE), is gaining recognition beyond
oncology for its potential in anti-inflammatory therapy. This review elucidates Selinexor's …
oncology for its potential in anti-inflammatory therapy. This review elucidates Selinexor's …
Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial
A Salawu, ER Malone, E Al-Ezzi, S Genta… - Targeted Oncology, 2024 - Springer
Background The approved dose of Selinexor, 60 mg twice-weekly, is associated with
several clinically relevant toxicities. Preclinical studies show that a sustained-release …
several clinically relevant toxicities. Preclinical studies show that a sustained-release …
Selinexor and Other Selective Inhibitors of Nuclear Export (SINEs)—A Novel Approach to Target Hematologic Malignancies and Solid Tumors
K Karaszewski, WW Jędrzejczak - Drugs and Drug Candidates, 2023 - mdpi.com
Exportin 1 (XPO1) is a crucial molecule of nucleocytoplasmic transport. Among others, it
exports molecules important for oncogenesis from the nucleus to the cytoplasm. The …
exports molecules important for oncogenesis from the nucleus to the cytoplasm. The …